StockData

Eloxx Pharmaceuticals vs Evaxion A/S

ELOX and EVAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ELOX and EVAX compare

Evaxion A/S grew revenue faster over the last twelve months (125% versus −100% for Eloxx Pharmaceuticals).

Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 2 for Evaxion A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricELOXEVAX
Size and price
Market cap$51.5M–
Share price$12.75$2.77
Change, 1 year1158990%−51.5%
Change, 5 years−97.9%−98.9%
Beta (5Y)–1.29
Employees745
StockData Score
Total score7 (better)2
Valuation score1 (better)0
Growth score01 (better)
Performance score1 (better)0
Health score5 (better)1
Dividend score00
Valuation
P/B1.1×–
Growth
Revenue growth (TTM)−100%125% (better)
Profitability
Operating margin–−123%
Net margin–−102%
FCF margin–−88.2%
Return on equity−54.3%–
Financial health
Debt / equity0.00–
Interest coverage–−2.3×
Current ratio3.745.06 (better)
Altman Z-score−4.46–
Piotroski F-score35 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%–
Ownership
Held by institutions71.8%0.38%
Held by insiders42.6%3.5%
Short interest, % of float2.3%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.